Ex­clu­sive: Hori­zon CEO Tim Wal­bert talks M&A, FTC post-Am­gen deal close

For 10 months, the bio­phar­ma in­dus­try wait­ed to see if Am­gen and Hori­zon Ther­a­peu­tics would pre­vail in their $27.8 bil­lion merg­er fol­low­ing scruti­ny and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER